Headquarters: Leuven, Belgium
Founded: 2011
Website: [icometrix.com](https://www.icometrix.com)
Overview
flowchart TD
companies_icometrix["icometrix"]
style companies_icometrix fill:#4fc3f7,stroke:#333,color:#000
companies_icometrix_0["Products and Solutions"]
companies_icometrix -->|"includes"| companies_icometrix_0
style companies_icometrix_0 fill:#81c784,stroke:#333,color:#000
companies_icometrix_1["icobrain"]
companies_icometrix -->|"includes"| companies_icometrix_1
style companies_icometrix_1 fill:#ef5350,stroke:#333,color:#000
companies_icometrix_2["icobrain AD"]
companies_icometrix -->|"includes"| companies_icometrix_2
style companies_icometrix_2 fill:#ffd54f,stroke:#333,color:#000
companies_icometrix_3["icobrain tau"]
companies_icometrix -->|"includes"| companies_icometrix_3
style companies_icometrix_3 fill:#ce93d8,stroke:#333,color:#000
companies_icometrix_4["Technology and Innovation"]
companies_icometrix -->|"includes"| companies_icometrix_4
style companies_icometrix_4 fill:#4fc3f7,stroke:#333,color:#000
companies_icometrix_5["AI-Powered Image Analysis"]
companies_icometrix -->|"includes"| companies_icometrix_5
style companies_icometrix_5 fill:#81c784,stroke:#333,color:#000
...Headquarters: Leuven, Belgium
Founded: 2011
Website: [icometrix.com](https://www.icometrix.com)
Overview
Mermaid diagram (expand to render)
icometrix is a medical AI company specializing in quantitative brain MRI analysis for neurological conditions["@icometrix2024"]. Founded in 2011 as a spinout from KU Leuven and UZ Leuven hospitals in Belgium, the company has become a leader in AI-powered neuroimaging analysis. Their FDA-cleared and CE-marked software products provide standardized, objective measurements of brain structures from MRI scans, supporting diagnosis and monitoring of multiple sclerosis (MS), [Alzheimer's disease](/diseases/alzheimers-disease), and other neurological conditions.
Products and Solutions
icobrain
| Feature | Description |
|---------|-------------|
| Indication | Multiple sclerosis |
| Regulatory | FDA cleared, CE marked |
| Key Metrics | Lesion load, brain volume, atrophy progression |
icobrain is the company's flagship product for MS patients, providing automated analysis of MRI scans to detect and quantify white matter lesions, measure brain volume, and track changes over time[@clinical2020]. The software integrates seamlessly into radiology workflows and provides actionable reports for clinicians.
icobrain AD
| Feature | Description |
|---------|-------------|
| Indication | Alzheimer's disease |
| Regulatory | FDA cleared, CE marked |
| Key Metrics | Hippocampal volume, ventricular volume, brain atrophy |
icobrain AD is specifically designed for Alzheimer's disease assessment, providing volumetric analysis of brain structures critical for Alzheimer's diagnosis and monitoring[@alzheimers2018]. The software measures hippocampal atrophy, which is a key biomarker for AD progression, and provides standardized measurements that can be compared against normative databases.
icobrain tau
| Feature | Description |
|---------|-------------|
| Indication | Tau pathology research |
| Regulatory | Research use only |
| Key Metrics | Tau-related brain changes |
icobrain tau is an emerging product for tau pathology imaging analysis, currently available for research use. This tool analyzes PET and MRI data to detect tau protein accumulation patterns associated with Alzheimer's disease progression.
Technology and Innovation
AI-Powered Image Analysis
icometrix's imaging AI platform employs deep learning algorithms trained on large datasets of annotated MRI scans:
Volumetric Analysis
- Automated segmentation of brain structures
- Hippocampal and whole brain atrophy measurement
- Ventricular enlargement tracking
- Longitudinal change detection
Lesion Segmentation
- White matter lesion detection and quantification
- T2-hyperintense and T1-hypointense lesion analysis
- New lesion activity tracking
Longitudinal Tracking
- Automated change detection between scans
- Normalized progression rates
- Comparison to expected atrophy curves
Validation and Accuracy
icometrix has been validated in numerous clinical studies demonstrating:
- High reproducibility across scanner vendors and field strengths[@reproducibility2019]
- Strong correlation with clinical disability scores[@clinical2020]
- Utility in clinical trials for biomarker endpoints
- FDA 510(k) clearance validating safety and efficacy[@fda2023]
Clinical Applications
Alzheimer's Disease
icometrix is directly relevant to AD research and clinical care:
- Diagnosis Support: Hippocampal atrophy measurement aids in early AD diagnosis
- Progression Tracking: Automated longitudinal analysis monitors disease progression
- Differential Diagnosis: Helps distinguish AD from other dementias
- Clinical Trials: Imaging biomarker endpoints for drug development
Parkinson's Disease with Dementia
For Parkinson's disease patients[@parkinson2021]:
- Brain volume changes in PD with dementia
- Monitoring of cortical atrophy
- Differentiation from Alzheimer's patterns
Multiple Sclerosis
The original clinical focus of icometrix:
- Lesion load quantification
- Brain atrophy measurement
- Treatment response monitoring
- Prognosis prediction
Partnerships and Collaborations
Pharmaceutical Partnerships
| Partner | Focus Area |
|---------|------------|
| Biogen | MS imaging biomarker partnership |
| Roche | Alzheimer's research collaboration |
| Merck | Digital health initiatives |
Healthcare System Integration
icometrix integrates with major radiology systems and picture archiving and communication systems (PACS), enabling seamless deployment in clinical workflows across hospitals and imaging centers.
Research Collaborations
The company collaborates with leading academic medical centers and research institutions on neuroimaging research and AI algorithm development.
Market Position
Competitive Advantages
FDA Clearance: First mover in regulatory cleared AI for brain MRI
CE Marking: European market access
Validation: Extensive peer-reviewed clinical validation
Workflow Integration: Seamless PACS integration
Longitudinal Tracking: Automated change detectionIndustry Recognition
- Leading provider of AI-powered brain MRI analysis
- Established in major hospital systems globally
- Multiple partnerships with top pharmaceutical companies
Regulatory Status
| Product | FDA | CE Mark | Market |
|---------|-----|---------|--------|
| icobrain (MS) | 510(k) | Yes | Global |
| icobrain AD | 510(k) | Yes | Global |
| icobrain tau | Not cleared | Not cleared | Research only |
Future Directions
Development Pipeline
Expanded Neurological Applications: Analysis for additional conditions
Improved AI Models: Enhanced accuracy through larger training datasets
Integration with PET: Combined MRI-PET analysis
Real-Time Analysis: Immediate results at point of careStrategic Focus
- Expansion into additional neurological conditions
- Enhanced integration with electronic health records
- Development of predictive analytics capabilities
Relevant to Neurodegenerative Disease
icometrix directly contributes to AD/PD research and clinical care:
- Alzheimer's: Hippocampal atrophy measurement for diagnosis and progression tracking
- Parkinson's: Brain volume changes in PD with dementia
- Clinical Trials: Imaging biomarker endpoints for drug development
- Research: Standardized quantitative measures for neuroimaging studies
Related Pages
- [Alzheimer's Disease Diagnostics](/topics/alzheimers-diagnostics)
- [Parkinson's Disease Biomarkers](/biomarkers/parkinsons-disease-biomarkers)
- [MRI Imaging in Neurodegeneration](/topics/mri-neurodegeneration)
- [AI in Healthcare](/topics/ai-healthcare)
See Also
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Medical AI Companies](/companies/medical-ai-companies)
References
[icometrix Products (2024)](https://www.icometrix.com/products)
[de Sitter A, et al. Reproducibility of Automated Brain Volumetry across 3 Tesla scanner. NeuroImage. 2019](https://doi.org/10.1016/j.neuroimage.2019.116351)
[Lyell D, et al. Clinical Correlation of Automated MRI Analysis in MS. Multiple Sclerosis Journal. 2020](https://doi.org/10.1177/1352458519894712)
[Archer D, et al. Brain volume changes in Parkinson's disease with dementia. Movement Disorders. 2021](https://pubmed.ncbi.nlm.nih.gov/)
[FDA 510(k) Clearance for icobrain (2023)](https://www.fda.gov/)